TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28419379

Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic to myofascial trigger points (MTrPs)
Number of subjects: 31
Study: 26869680

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-to-Moderate Intensity Exercise (LMIE)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both HIIT and LMIE
Number of subjects: 28
Study: 25122980

Group type: EXPERIMENTAL
Intervention: Chewing gum containing calcium hydroxyapatite
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo chewing gum (control)
Number of subjects: 107
Study: 23029823

Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Catheter drainage
Number of subjects: 45
Study: 20618973

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model adjusted for differences in study arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unadjusted results for combined studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggregate study values adjustment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downweighting method 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downweighting method 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised studies alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomised studies alone
Number of subjects: 0
Study: 17215177

Group type: EXPERIMENTAL
Intervention: Water soluble calcium hydroxycitrate (HCA) as Garcinia atroviridis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15543337

Group type: EXPERIMENTAL
Intervention: B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 11919401

Group type: EXPERIMENTAL
Intervention: Diabetes duration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Abnormal proteinuria
Number of subjects: 98
Study: 9598714

Group type: EXPERIMENTAL
Intervention: Behavioral counseling + cognitive-behavioral mood management (CBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Behavioral counseling (BC)
Number of subjects: 29
Study: 9124839

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1,000 mg)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 832
Study: 2174933

Group type: EXPERIMENTAL
Intervention: Repeated chemoembolization with gelfoam powder and doxorubicin (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Symptomatic treatment (group 2)
Number of subjects: 42
Study: 7013960

Group type: EXPERIMENTAL
Intervention: Combination therapy with diethylstilbestrol, cyclophosphamide, and 5‐fluorouracil (DES + CTx + FU)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sequential therapy (DES leads to CTx + FU)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 87
Study: 31907006

Group type: EXPERIMENTAL
Intervention: 120,000 IU/month of vitamin D (cholecalciferol) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo for 6 months
Number of subjects: 0
Study: 31094991

Group type: EXPERIMENTAL
Intervention: Intramedullary (IM) nailing
Number of subjects: 30

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 30
Study: 29029644

Group type: EXPERIMENTAL
Intervention: 6-month dispensing of ART
Number of subjects: 8200

Group type: EXPERIMENTAL
Intervention: 3-month dispensing of ART
Number of subjects: 8200

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 8200
Study: 24108196

Group type: EXPERIMENTAL
Intervention: Transvaginal cholecystectomy (TVC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40
Study: 24131035

Group type: EXPERIMENTAL
Intervention: Secular song reminiscence (n=13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Religious song reminiscence (n=13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard story reminiscence (n=14)
Number of subjects: 40
Study: 22456300

Group type: EXPERIMENTAL
Intervention: semagacestat 140 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: semagacestat 280 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 20139231

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18084118

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no pitavastatin)
Number of subjects: 101
Study: 16238507

Group type: EXPERIMENTAL
Intervention: Combined meditation and massage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Meditation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study: 11851662

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 300

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 300
Study: 10440399

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 154
Study: 7799083

Group type: EXPERIMENTAL
Intervention: 99mTc‐sestamibi imaging
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (gender-matched subjects with low pre-test likelihood of CAD)
Number of subjects: 72
Study: 1980464

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All drugs (Lormetazepam and Flurazepam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 367976

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 110
Study: 28865911

Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy (TMT; VRET plus a group treatment for anger, depression, and social isolation)
Number of subjects: 92

Group type: COMPARATOR
Intervention: VRET plus a psychoeducation control condition
Number of subjects: 92
Study: 29336615

Group type: EXPERIMENTAL
Intervention: Ornibel® (etonogestrel/ethinylestradiol 11.00/3.47 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)
Number of subjects: 40
Study: 26118527

Group type: EXPERIMENTAL
Intervention: Self myofascial release (SMR) via a tennis ball to the plantar aspect of the foot
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 24
Study: 23812209

Group type: EXPERIMENTAL
Intervention: NexGen LPS Gender Solutions (GS) prosthesis
Number of subjects: 80

Group type: COMPARATOR
Intervention: NexGen LPS Flex (ST) prosthesis
Number of subjects: 80
Study: 21820719

Group type: COMPARATOR
Intervention: 1.5 mM glucose (Group A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.15 mM glucose (Group B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.125 mM G3P with 0.15 mM glucose (Group C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.34 mM citrate with 2.77 mM myo‐inositol (Group D)
Number of subjects: 4
Study: 19493153

Group type: EXPERIMENTAL
Intervention: ICD plus appropriate medical therapy
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1550
Study: 17074344

Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: rhCG (250 microg)
Number of subjects: 60
Study: 15543464

Group type: EXPERIMENTAL
Intervention: Myoelectric control strategy using MES from wrist flexor and extensor muscles
Number of subjects: 7
Study: 12101821

Group type: EXPERIMENTAL
Intervention: Regular exercise and low fat diet (walking 60 minutes daily, <20% total fat, 300 mg/d cholesterol)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Regular exercise and low fat diet
Number of subjects: 62
Study: 9773699

Group type: EXPERIMENTAL
Intervention: ISBPB with 10 mL 0.125% bupivacaine with epinephrine 1:400,000 (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (n = 15)
Number of subjects: 30
Study: 9791777

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard approach to postoperative analgesia (intramuscular injections on an 'as needed' basis)
Number of subjects: 60
Study: 2201481

Group type: EXPERIMENTAL
Intervention: Clovoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 410298

Group type: EXPERIMENTAL
Intervention: Low-dose Rho(D) immune globulin (human)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up testing of immune globulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single low-dose immune globulin preparations
Number of subjects: 0
Study: 31225625

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4, 2.4, 5.2, 15.8 mg/g)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes
Number of subjects: 169
Study: 30966820

Group type: COMPARATOR
Intervention: Preserved LVEF (LVEF ≥ 50%)
Number of subjects: 6198

Group type: COMPARATOR
Intervention: Mid-range reduced LVEF (LVEF 40-49%)
Number of subjects: 6198

Group type: EXPERIMENTAL
Intervention: Reduced LVEF (LVEF < 40%)
Number of subjects: 6198
Study: 28542742

Group type: EXPERIMENTAL
Intervention: Exercise intervention (4 NHs, n = 47)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Social activity intervention (3 NHs, n = 50)
Number of subjects: 97
Study: 26361969

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg oral, twice a day for a maximum of 4 years)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Placebo (twice a day for a maximum of 4 years)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1114
Study: 23574730

Group type: EXPERIMENTAL
Intervention: Miglitol (150 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 35
Study: 20880294

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 18449573

Group type: EXPERIMENTAL
Intervention: Double lumen totally implantable subcutaneous port system (PORT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Double lumen central venous catheter (CVC)
Number of subjects: 32
Study: 17109447

Group type: EXPERIMENTAL
Intervention: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with paclitaxel (70 mg/m2)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with vinorelbine (25 mg/m2)
Number of subjects: 66
Study: 15701228

Group type: EXPERIMENTAL
Intervention: Stimuli presented to the right cerebral hemisphere during individuation tasks.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Stimuli presented to the left cerebral hemisphere during individuation tasks.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Neuroimaging investigation of individuation tasks.
Number of subjects: 2
Study: 11723527

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg administered twice daily via a breath‐activated, multi‐dose, dry‐powder inhaler
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9387000

Group type: EXPERIMENTAL
Intervention: False feedback of wheezing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quiet respiratory sounds
Number of subjects: 90

Group type: COMPARATOR
Intervention: No sound
Number of subjects: 90
Study: 7898966

Group type: EXPERIMENTAL
Intervention: New radiographic scoring system for bronchopulmonary dysplasia (BPD)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Edwards score
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: New radiographic scoring system for BPD
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroid use
Number of subjects: 366
Study: 2730857

Group type: EXPERIMENTAL
Intervention: NODS 40 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NODS 80 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NODS 170 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional eyedrop (2% Minims, 518 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comparison of total doses delivered
Number of subjects: 8
Study: 30133324

Group type: EXPERIMENTAL
Intervention: Recovery from disuse in healthy men after 1-leg cast immobilization and reloading.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mice undergoing reloading after hindlimb suspension.
Number of subjects: 0
Study: 27906554

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) in the evening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) in the morning
Number of subjects: 0
Study: 25875541

Group type: EXPERIMENTAL
Intervention: Warmed (37°C), humidified (98%) insufflation carbon dioxide
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard gas (19°C, 0%)
Number of subjects: 82
Study: 23161124

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 100
Study: 21538524

Group type: EXPERIMENTAL
Intervention: Levetiracetam (up to 2000 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 16
Study: 18504551

Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional glycemic control
Number of subjects: 72
Study: 16418093

Group type: EXPERIMENTAL
Intervention: CPR performed on the floor
Number of subjects: 62

Group type: COMPARATOR
Intervention: CPR performed on a moving stretcher
Number of subjects: 62
Study: 14520143

Group type: EXPERIMENTAL
Intervention: Linezolid 10 mg/kg iv every 8 h (with option to switch to oral linezolid 10 mg/kg every 8 h)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vancomycin 10 to 15 mg/kg every 6 to 24 h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Linezolid and Vancomycin
Number of subjects: 120
Study: 11090730

Group type: COMPARATOR
Intervention: succinylcholine 1.5 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rocuronium bromide 0.6 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: atracurium
Number of subjects: 30
Study: 8982415

Group type: EXPERIMENTAL
Intervention: Tap water iontophoresis in addition to two-sided steroid-free topical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side (not treated with tap water iontophoresis)
Number of subjects: 20
Study: 1547175

Group type: EXPERIMENTAL
Intervention: Surgical adhesiolysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 48
Study: 3903678

Group type: EXPERIMENTAL
Intervention: UVB (group B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: UVAB (group AB)
Number of subjects: 106
Study: 31091508

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.6 mg/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ketorolac (30 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 126
Study: 28779006

Group type: EXPERIMENTAL
Intervention: TREX dosing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monthly dosing transitioned to PRN
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TREX subjects transitioned to PRN
Number of subjects: 60
Study: 27599170

Group type: EXPERIMENTAL
Intervention: Massage with lotion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Massage without lotion
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-massage control
Number of subjects: 76
Study: 24667391

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (1.2 μg kg(‐1) min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular dose remifentanil (0.2 μg kg(‐1) min(‐1))
Number of subjects: 60
Study: 22464116

Group type: EXPERIMENTAL
Intervention: Pilates-based therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 31
Study: 20421611

Group type: EXPERIMENTAL
Intervention: English vocabulary instruction enhanced with Spanish bridging
Number of subjects: 22

Group type: COMPARATOR
Intervention: English-only vocabulary instruction
Number of subjects: 22
Study: 18362931

Group type: EXPERIMENTAL
Intervention: Aex plus GM-CSF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aex alone
Number of subjects: 40
Study: 16036128

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide and resin‐modified glass ionomer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dentin hybridization only
Number of subjects: 60
Study: 12611359

Group type: EXPERIMENTAL
Intervention: LF-ASD brain-controlled switch with imagined voluntary movements (able-bodied subjects)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LF-ASD brain-controlled switch with imagined voluntary movements (spinal-cord injury subjects)
Number of subjects: 4
Study: 10337843

Group type: EXPERIMENTAL
Intervention: Caregiving Effectiveness Model variables
Number of subjects: 62
Study: 7492155

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate (n = 27)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate (n = 32)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual diet (Control group, n = 26)
Number of subjects: 85
Study: 1855355

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 74
Study: 7073809

Group type: EXPERIMENTAL
Intervention: Diflorasone diacetate ointment 0.05%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment 0.05%
Number of subjects: 100
Study: 31525673

Group type: EXPERIMENTAL
Intervention: REHACOM computerized cognitive remediation intervention (n = 36)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Active control condition (n = 50) consisting of 24 one-hour sessions addressed twice a week
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (REHACOM and control)
Number of subjects: 86
Study: 29056103

Group type: EXPERIMENTAL
Intervention: Targeted dietary advice solutions developed per metabotype using a decision tree approach.
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Personalised dietary advice delivered by nutritionists to Food4Me study participants.
Number of subjects: 1607
Study: 26573024

Group type: EXPERIMENTAL
Intervention: Clomiphene-HMG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Letrozole-HMG
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-LUF group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Follicle size 18-19.9 mm
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Follicle size 20-21.9 mm
Number of subjects: 180
Study: 25018097

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Control (Hepatitis A vaccine)
Number of subjects: 7466
Study: 21102369

Group type: EXPERIMENTAL
Intervention: Lidocaine pledget
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical proparacaine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical tetracaine
Number of subjects: 24
Study: 19302646

Group type: EXPERIMENTAL
Intervention: Frova single-use tracheal tube introducer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Eschmann multiple-use introducer
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pro-Breathe single-use tracheal tube introducer
Number of subjects: 72

Group type: COMPARATOR
Intervention: new Portex single-use tracheal tube introducer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pro-Breathe, new Portex, and Frova single-use introducers
Number of subjects: 72
Study: 17319771

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC adhesive
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transbond Plus system
Number of subjects: 40
Study: 14998806

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11448899

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 25 mg HRS‐3/A9 for 4 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of 25 mg HRS‐3/A9 every other day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interleukin 2 pretreatment before the second BiMAb course
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HRS‐3/A9 treatment
Number of subjects: 16
Study: 9602194

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (≤ 20 ppm for 1 to 4 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitrotyrosine detection
Number of subjects: 24
Study: 7985146

Group type: EXPERIMENTAL
Intervention: Transcardiac galvanization (TG)
Number of subjects: 110
Study: 2662065

Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (Naprosyn CR), 750 mg daily
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard Naprosyn, 750 mg daily
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (Naprosyn CR)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard Naprosyn
Number of subjects: 520
Study: 29558822

Group type: EXPERIMENTAL
Intervention: AHCC®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28972245

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 246